A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
AstraZeneca
Summary
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Description
This is a multi-centre and multinational basket study that will monitor the long-term safety and tolerability of cell or gene therapies in participants that have taken part in other AstraZeneca cell or gene therapy studies for up to 15 years.
Eligibility
- Age range
- 18–130 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. The participant has received a cell or gene therapy in another AstraZeneca protocol. 2. Provision of signed and dated, written informed consent before any study-specific procedures. Exclusion Criteria: Not applicable \-
Interventions
- BiologicalAZD5851
Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
- BiologicalAZD0754
Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
Locations (25)
- Research SitePhoenix, Arizona
- Research SiteDuarte, California
- Research SiteOrange, California
- Research SiteSan Francisco, California
- Research SiteWashington D.C., District of Columbia
- Research SiteJacksonville, Florida